Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
Annals of Hematology|March 16, 2013
The evolving use of arsenic in pharmacotherapy of malignant diseaseAthena Kritharis, Thomas P Bradley, Daniel R BudmanMolecular Medicine (Cambridge, Mass.)|December 1, 2012
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancerMyra F Barginear, Veena John, Daniel R BudmanFuture Oncology (London, England)|March 30, 2016
Immune checkpoint inhibitors in lung cancer: past, present and futureNagashree Seetharamu, Daniel R Budman, Kevin M SullivanBiologics : Targets & Therapy|August 27, 2009
Novel microtubule-targeting agents - the epothilonesKit L Cheng, Thomas Bradley, Daniel R BudmanCritical Reviews in Oncology/Hematology|June 13, 2013
P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potencyIuliana Shapira, Annette Lee, Reena Vora, et al.Molecular Medicine (Cambridge, Mass.)|September 26, 2018
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeuticsKarie Runcie, Daniel R Budman, Veena John, et al.Investigational New Drugs|June 10, 2010
The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell linesDaniel R Budman, Julia Tai, Anthony Calabro, et al.Critical Reviews in Oncology/Hematology|February 11, 2010
Emerging role of small ribonucleic acids in gastrointestinal tumorsIuliana Shapira, Keith Sultan, Bhoomi Mehrotra, et al.Anti-Cancer Drugs|February 22, 2013
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model systemDaniel R Budman, Anthony Calabro, Lisa Rosen, et al.Current Treatment Options in Oncology|April 11, 2009
Adjuvant chemotherapy for early breast cancer in the elderlyMary Leung, Iulianna Shapira, Thomas Bradley, et al.Pageof 4